Brief: Kintor Pharmaceutical Says Clinical Trial Of Kx-826 Tincture 1.0% Cleared By NMPA
24/05/2024 09:11
May 24 (Reuters) - Kintor Pharmaceutical Ltd 9939.HK :
* CLINICAL TRIAL OF KX-826 TINCTURE 1.0% IN CHINA RECEIVED
CLEARANCE BY NMPA
Further company coverage: 9939.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kintor Pharmaceutical
See all newsBrief: Kintor Pharmaceutical Receives Invention Patent Grant For KT-939 In China
Brief: Kintor Pharmaceutical Says Ming Ming Cheung Resigns As CFO
Brief: Kintor Pharmaceutical Says CEO Via Wholly Owned Co Increases Shareholding By 2.51 Million Shares
Brief: Kintor Pharmaceutical Says YTD 2026 Sales Revenue At RMB34 Million
Brief: Kintor Pharmaceutical Says Pharma's Kx-826 Phase Iii Trial In China Reaches Primary Endpoint